Abstract library

23 results for "inflammation".
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Biomarkers
Presenting Author: David L Chan
#1436 Up-Regulation of the Immunoregulatory Enzyme Indoleamine-2,3-Dioxygenase (IDO) with Consecutive Tryptophan Depletion Predicts Death in Patients with Neuroendocrine Neoplasia
Introduction: Data from a considerable number of malignancies demonstrate that depletion of the essential amino acid tryptophan via induction of the immuno-regulatory enzyme Indoleamine-2,3-dioxygenase (IDO) serves as an important tumour escape strategy and is of prognostical importance.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Pape U F, Fusch G, Jann H, ...
#1893 Peripheral Blood Biomarkers of Systemic Inflammation May Be Prognostic in Metastatic Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) Patients Following 177Lu-DOTATATE (LuTate)
Introduction: LuTate is a treatment for well-differentiated NETs with adequate somatostatin receptor expression. Prognostic biomarkers in this population are lacking. Neutrophil-to-lymphocyte ratio (NLR) is prognostic in the majority of solid tumours but is reported to have less value in indolent well-differentiated NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Aimee Hayes
#1311 Blood-Based Prognostic Biomarkers in Neuroendocrine Tumour: A Retrospective Study
Introduction: Markers of systemic inflammation –such as the neutrophil:lymphocyte ratio (NLR), platelet:lymphocyte ratio (PLR) and lymphocyte:monocyte ratio (LMR) - have been shown to correlate with poor prognosis in multiple solid organ tumours. Analysis of CLARINET showed no significant association between NLR and progression-free survival.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Biomarkers
Presenting Author: Dr David Chan
Authors: Diakos C, Chan D, Gurney E, Bailey D, ...
Keywords: NLR, biomarker
#1740 A Nomogram Consisted of Routine Biochemical Tests May Increase the Diagnostic Accuracy of Chromogranin A in Detecting Patients with Neuroendocrine Tumors
Introduction: Serum chromogranin A (CgA) may be falsley increased in patients with renal impairment and systemic inflammation.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: MD, PhD Ivan Kruljac
#1810 FOXM1 Is Strongly Associated with Cell Proliferation and Is Not Influenced by Metabolic Syndrome in GEP-NETS
Introduction: Gastro-entero-pancreatic neuroendocrine tumors(GEP-NETs) and metabolic syndrome(MS) are both increasing exponentially. MS has been associated with several non NET cancers.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr. Ana Paula Santos
#2172 Well-Differentiated Neuroendocrine Lesions in Inflammatory Bowel Disease
Introduction: Whether inflammatory Bowel disease (IBD) increases the risk of developing neuroendocrine tumors (NETs) is not clear. NETs are rare in IBD, though one recent report suggests that NETs are 15 times more frequent in patients with Crohn’s disease. Besides NETs, which are discrete mass-forming lesions, microscopic neuroendocrine cell clusters or micronests (NEMs), difficult to measure, are sometimes observed in the lamina propria/muscularis mucosae of IBD patients.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Pathology - grading, staging
Presenting Author: Deepti Dhalld
Authors: Dhall D, Wong M, Larson B, ...
#2198 PD-L1 Expression and Its Clinical Relevance in Neuroendocrine Tumors of the Lung
Introduction: Immune checkpoint regulation seems to be crucial for nonneuroendocrine lung cancer patients. However, little is known in lung neuroendocrine tumors.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Atsuko Kasajima
Keywords: Lung NEN, PD-L1, Prognosis
#2301 Trends in Management of Gastro-Intestinal Neuroendocrine Tumors in Inflammatory Bowel Diseases: The Contribute of a Case Series.
Introduction: The risk to develop gastro-intestinal malignancies is higher in patients affected by inflammatory bowel diseases (IBD). Apart from colo-rectal cancer, related to a long standing inflammation, there is a growing evidence of neuroendocrine tumors (NETs) in these patients and a correlation between these two diseases has been postulated. We report four cases of NETs in IBD.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Doctor Stefano Rizza
#2970 Characteristics, Treatments and Inflammatory Biomarkers in Patients (pts) with G3 Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs)
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Soledad Cameselle-Garcia